唑来磷酸防治芳香化酶抑制剂相关骨丢失临床研究进展

芳香化酶抑制剂（aromatase inhibitor,AI）已逐渐成为绝经后乳腺癌患者内分泌治疗的标准疗法,但由于AI显著降低循环中雌激素水平,导致骨丢失增加,增加骨质疏松症和骨折发生的风险。因此,早期认识、预防和治疗AI诱导的骨丢失是非常有必要的。唑来磷酸是破骨细胞的特异性抑制剂,目前广泛应用于转移性骨病的治疗。近年来已有多个临床研究报道唑来磷酸能够防治绝经后乳腺癌患者中芳香化酶抑制剂相关骨丢失,降低骨折发生率。本文就唑来磷酸防治绝经后乳腺癌患者中芳香化酶抑制剂相关骨丢失的临床研究进展进行综述。

Development of clinical researches on prevention aromatase inhibitor-associated bone loss by zoledronic acid

Aromatase inhibitors（AIs） are standard therpy for postmenopausal women with estrogen responsive breast cancers.By inhibiting the aromatase enzyme,causing decreases in endogenous estrogens,the treatment of Als is responsible for lower bone mineral density（BMD） and increased fractures.Therefore,early recognition, prevention,and/or treatment of AI-induced bone loss is needed.Zoledronic acid is specific inhibitors of osteoclasts and extensively used in bone metastasis patients.Recently, there are several trials evaluating the use of intravenous zoledronic acid as prevention and treatment of AI-induced bone loss in postmenopausal women with breast cancer.In this article, we aim to review the use of zoledronic acid in this population including the response and safety.